$117.570
+5.926 (+5.04%)收盤時
MNPR 同業比較
In the context of the broader market, MNPR competes directly with industry leaders such as AURA and NGNE. With a market capitalization of $789.15M, it holds a leading position in the sector. When comparing efficiency, MNPR's gross margin of N/A stands against AURA's N/A and NGNE's N/A. Such benchmarking helps identify whether Monopar Therapeutics Inc. is trading at a premium or discount relative to its financial performance.
Monopar Therapeutics Inc 財務表現
The company has faced significant net losses, with Q2 2026 net income at -5,313,300 USD, but it has shown a positive EPS of 0.62 in Q2 2026, indicating potential recovery.
Financials
FY2026Q2
YoY:
+105.44%
-6.64M
Operating Profit
FY2026Q2
YoY:
+116.56%
-5.31M
Net Income after Tax
FY2026Q2
YoY:
+77.14%
-0.62
EPS - Diluted
FY2026Q1
YoY:
-38.66%
-3.47M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。